US 12,479,886 B2
Inhibitors of IL-15 and their use in treating autoimmune/inflammatory disorders
Bin Guo, Sugar Land, TX (US); Gomika Udugamasooriya, Katy, TX (US); Satya Prakash Shukla, Houston, TX (US); Kwang Bog Cho, Houston, TX (US); and Shuang Zhou, Houston, TX (US)
Assigned to University of Houston System, Houston, TX (US)
Appl. No. 17/624,523
Filed by University of Houston System, Houston, TX (US)
PCT Filed Jun. 30, 2020, PCT No. PCT/US2020/040324
§ 371(c)(1), (2) Date Jan. 3, 2022,
PCT Pub. No. WO2021/003171, PCT Pub. Date Jan. 7, 2021.
Claims priority of provisional application 62/870,318, filed on Jul. 3, 2019.
Prior Publication US 2022/0242907 A1, Aug. 4, 2022
Int. Cl. C07K 7/06 (2006.01); A61K 38/08 (2019.01); A61K 45/06 (2006.01); A61P 29/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/06 (2013.01) [A61K 38/08 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01); A61K 38/00 (2013.01)] 9 Claims
 
1. A method of inhibiting IL-15 signaling in a human subject comprising administering to said subject an effective amount of a peptoid multimer having the following structure:
wherein the multimer has a structure selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein the human subject is a pediatric patient, a teenager, or an adult.